Realm Therapeutics : Presentation at RBC Healthcare Conference

Realm Therapeutics to Present at the RBC Capital Markets 2018 Global Healthcare Conference

MALVERN, PA, February 20, 2018- Realm Therapeutics plc (AIM:RLM), a clinical stage biopharmaceutical company focused on developing novel therapeutics in immune-mediated diseases, announced today that Alex Martin, CEO, will be presenting at the RBC Capital Markets 2018 Global Healthcare Conference, on Thursday, February 22, 2018 at 8:00 a.m. ET at the Lotte New York Palace.

A live and archived webcast of the RBC presentation will be available on the Events and Presentations page of the Company's website. An updated copy of Realm's corporate presentation is available on the Company's website atwww.realmtx.com.

About Realm Therapeutics

Realm Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapeutics that target the intersection between innate and adaptive immunity, to influence immune signaling and change the course of immune-mediated diseases in adults and children. Realm's lead drug development programs utilize the Company's proprietary immunomodulatory technology for the treatment of Allergic Conjunctivitis (PR013) and Atopic Dermatitis (PR022) and Realm is exploring its efficacy in additional Ophthalmology and Dermatology indications as well as other disease areas. For more information on Realm Therapeutics, Inc. please visitwww.realmtx.com.

Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

Contact:

Realm Therapeutics plc

Alex Martin, Chief Executive Officer

Marella Thorell, Chief Financial Officer and Chief Operating Officer

Outside US: +44 (0) 20 3727 1000

US: +1 212 600 1902

Argot Partners

Stephanie Marks

+1 212 600 1902

FTI Consulting

Simon Conway / Mo Noonan

+44 (0) 20 3727 1000

N+1 Singer (Nominated Adviser and Broker) Aubrey Powell / Jen Boorer

+44 (0) 20 7496 3000